advertisement
11.13.2 Betablocker and carbon anhydrase inhibitor (7)
Showing records 1 to 7
Display all abstracts in classification 11.13.2 Betablocker and carbon anhydrase inhibitor
Search within classification 11.13.2 Betablocker and carbon anhydrase inhibitor60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Shimizu Y
Clinical Ophthalmology 2015; 9: 475-482
60147 Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study
García-López A
BMC Ophthalmology 2014; 14: 161
60175 The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
Radcliffe NM
Clinical Ophthalmology 2014; 8: 2541-2549
60147 Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study
Paczka JA
BMC Ophthalmology 2014; 14: 161
60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Nakakura S; Nishiyama M
Clinical Ophthalmology 2015; 9: 475-482
60147 Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study
Jiménez-Román J; Hartleben C
BMC Ophthalmology 2014; 14: 161
60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Tabuchi H; Kiuchi Y
Clinical Ophthalmology 2015; 9: 475-482
